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  Stellingen behorende bij het proefschrift.
  Overview of one decade developments of an EVAR endograft
 1.  Tailor-made treatment using pharmacological pathways to stop or reverse aortic wall degradation, 
promoting aortic wall tissue regeneration and stabilization could reduce the number of operative 
treatment of AAAs. (Chapter 2)
 2.  Extracting EVAR suitability decision algorithms from a large panel of experienced clinicians has the 
potential to become an up to date selection tool of the best fi tting endograft according to patients 
individual anatomy if the algorithms are validated, easily accessible, and continuously updated with 
the outcome of EVAR. (Chapter 3)
 3.  The additional feature of being repositionable may add to more accurate placement of an endograft 
and overcome the problems associated with a fi rst-time suboptimal placement. (chapter 4)
 4.  The features of the second-generation AnacondaTM endograft, such as repositionability of the two 
proximal stent rings during deployment and the unsupported and therefore more fl exible main 
body, appear to expand the applicability of EVAR in AAA beyond 60 degrees of neck angulation. 
(Chapter 5)
 5.  rEVAR can be used in a damage control concept accepting less favorable AAA anatomies. 
(Chapter 6)
 6.  The substantial number of limb occlusions presenting between 2 and 5 years suggested an ongoing 
interaction between the anatomical confi guration and blood fl ow. (chapter 7)
 7.  Nationwide screening questions such as detecting lung cancer in the high-risk smoking group using 
a pulmonary CT-scan could be combined with fi rst time AAA screening and thereby improving the 
benefi t of otherwise screening nationwide. (Chapter 8)
 8.  Combining the knowledge and experience of vascular interventionalists and technical clinicians 
together in one vascular team should be the gold standard in AAA clinical and research programs. 
(Chapter 8)
 9.  “In het recht is altijd alles in goede handen. Het recht richt de samenleving.” Prof. Mr. Rinus Otte, 
lid college van procureurs-generaal OM in Medisch Contact, 15 maart 2018. 
 10.  Het is mondiaal niet eff ectief om de kolen en biomassa Eemshavencentrale met vermogen van 
1500 MW spoedig te sluiten als China voor 2020 met aankondiging en vergunningen al weer 
153.726 MW zal gaan bouwen. (bron data www.endcoal.org).
 11.  Tweedehands elektrische auto’s gekocht door onervaren en roekeloze bestuurders zijn vanwege 
massa,  acceleratie en geluidloosheid rijdende “tijdbommen” in het verkeer.
         Groningen, Augustus 2020
         Steff an Rödel  
